Xencor Licenses Antibody Optimization Technology Monrovia, Calif. – November 30, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology

Xencor Appoints Jeffrey V. Ravetch of The Rockefeller University to its Scientific Advisory Board Monrovia, CA—June 29, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, today announced the addition of Jeffrey Ravetch,

Drug well tolerated with early signs of efficacy in heavily pretreated Hodgkin lymphoma patient population

First clinical data from a candidate developed using Xencor's antibody engineering platform

Xencor Licenses Xtend ™ Antibody Half-life Prolongation Platform to Merck & Co., Inc. Monrovia, CA – March 23, 2009 – Xencor, Inc., an antibody discovery and development company, announced today that is has entered into a licensing transaction with Merck & Co., Inc.

Monrovia, CA – March 2, 2009. Xencor, Inc., an antibody discovery and development company, announced today that is has entered into a technology license and evaluation agreement with Pfizer Inc to optimize the performance of therapeutic monoclonal antibodies.

Xencor and CSL Limited Establish Antibody Optimization Collaboration Monrovia, CA – February 23, 2009 – Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd.

Xencor Presents Data from Pre-clinical Studies of its Anti-CD19 and Anti-CD40 Antibodies at the 50th Annual Meeting of the American Society of Hematology Monrovia, Calif. – December 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, presented results Sunday at the 50th

Xencor to Present New Data from Pre-Clinical Antibody Programs at Upcoming ASH Conference Monrovia, Calif. – December 2, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, will present new data from its pre-clinical anti-CD19 and anti-CD40 programs, XmAb®5574 and XmAb®5485

Xencor to Present New Data from Anti-CD19 Antibody Program at ASCO Monrovia, Calif. – June 1, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, announced today that it will present new data from pre-clinical studies evaluating XmAb®5574, an Fc engineered monoclonal